Glucagonoma pathophysiology

Revision as of 15:45, 2 August 2017 by Medhat (talk | contribs)
Jump to navigation Jump to search

Glucagonoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Glucagonoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glucagonoma pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glucagonoma pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glucagonoma pathophysiology

CDC on Glucagonoma pathophysiology

Glucagonoma pathophysiology in the news

Blogs on Glucagonoma pathophysiology

Directions to Hospitals Treating Glucagonoma

Risk calculators and risk factors for Glucagonoma pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Overview

A glucagonoma is a rare tumor of the alpha cells of the pancreas that results in the overproduction of the hormone glucagon. On microscopic histopathological analysis, findings of glucagonoma are epidermal necrosis, subcorneal pustules, confluent parakeratosis, epidermal hyperplasia and marked papillary dermal angioplasia, and suppurative folliculitis.

Pathogenesis

All cases of the glucagonoma have been associated with tumors originating in the alpha cells of the pancreas. Glucagon, acting on the liver, increases both amino acid oxidation and gluconeogenesis from amino acid substrates [6]. The weight loss characteristic of glucagonoma may result from the catabolic action of glucagon and through glucagon-like peptides such as GLP-1. Necrolytic migratory erythema probably results from hyponutrition and amino acid deficiency [7]. Diarrhea may result from hyperglucagonemia and co-secretion of gastrin, vasoactive intestinal peptide, serotonin, or calcitonin [2].

Pathogenesis of necrolytic migratory erythema is ill defined. The postulated mechanism for necrolytic migratory erythema involves the combined effect of hyperglucagonemia, zinc deficiency, fatty acid deficiency, hypoaminoacidemia, and liver disease, that lead to excessive inflammation in the epidermis in response to trauma and to the necrolysis.[1][2]

Genetics

Mahvah disease is due to a homozygous P86S mutation of the human glucagon receptor. It is associated with the development of α-cell hyperplasia, hyperglucagonemia, and the development of nonfunctioning pNETs. A second

disease called glucagon cell adenomatosis can mimic glucagonoma

syndrome clinically and is characterized by the presence of hyperplastic

islets staining positive for glucagon instead of a single glucagonoma.

Associated Conditions

Gross Pathology

  • Glucagonomas are neuroendocrine tumors derived from multipotential stem cells.
  • Glucagonomas are generally large tumors at diagnosis with a mean diameter of 5 cm, From 50 to 82% have evidence of metastatic spread at presentation.
  • Nearly all glucagonomas are located in the pancreas, 50–80% occur in the pancreatic tail, 32.2% in the body and 21.9% in the head.
  • In few patients, the location was extrapancreatic, such as in kidney, duodenum, lung, accessory pancreatic tissue.
  • Metastasis usually occurs to the liver. The most common site for distal metastases is the liver
  • Other sites are lymph nodes, bone, mesentery, lung, and adrenals. 22
  • Tumors below 2 cm in diameter are associated with a very low chance of malignancy.

Microscopic Pathology

  • Many glucagonomas are pleomorphic36,37 with cells containing granules that stain for other peptides, most frequently pancreatic polypeptide. 36,38
  • Glucagon is usually detectable within the tumor cells by immunoperoxidase staining, and glucagon mRNA may be detected.
  • Electron microscopy reveals a variable number of secretory granules, indicative of their alpha cell origin.
  • Benign tumors are usually fully granulated, whereas malignant cells have fewer granules. 35,39

Images

References

  1. Necrolytic migratory erythema. Wikipedia. https://en.wikipedia.org/wiki/Necrolytic_migratory_erythema. Accessed on October 13, 2015.
  2. Mullans EA, Cohen PR (1998). "Iatrogenic necrolytic migratory erythema: a case report and review of nonglucagonoma-associated necrolytic migratory erythema". J Am Acad Dermatol. 38 (5 Pt 2): 866–73. PMID 9591806.
  3. 3.0 3.1 3.2 3.3 Glucagonoma. Wikimedia Commons. https://commons.wikimedia.org/wiki/File:Confluent_epidermal_necrosis_-_high_mag.jpg
  4. Castro PG, de León AM, Trancón JG, Martínez PA, Alvarez Pérez JA, Fernández Fernández JC; et al. (2011). "Glucagonoma syndrome: a case report". J Med Case Rep. 5: 402. doi:10.1186/1752-1947-5-402. PMC 3171381. PMID 21859461.
  5. Fang S, Li S, Cai T (2014). "Glucagonoma syndrome: a case report with focus on skin disorders". Onco Targets Ther. 7: 1449–53. doi:10.2147/OTT.S66285. PMC 4140234. PMID 25152626.
  6. 6.0 6.1 6.2 Erdas E, Aste N, Pilloni L, Nicolosi A, Licheri S, Cappai A; et al. (2012). "Functioning glucagonoma associated with primary hyperparathyroidism: multiple endocrine neoplasia type 1 or incidental association?". BMC Cancer. 12: 614. doi:10.1186/1471-2407-12-614. PMC 3543729. PMID 23259638.


Template:WikiDoc Sources